Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2022.2039630
Abstract: ABSTRACT Introduction To date, four Janus kinase inhibitors (JAKis) are licensed for the treatment of rheumatoid arthritis (RA) and/or psoriatic arthritis (PsA) in North America and/or Europe: tofacitinib, baricitinib, upadacitinib, and filgotinib. Most DMARDs have… read more here.
Keywords: jak inhibitors; jaki; safety jak; risk ... See more keywords